MedDataX Logo

Lipid Rich Necrotic Core Lesion Detected by Cardiac Magnetic Resonance Imaging (CMR)

NCT ID: NCT01284270

Last Updated: 2013-09-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

NA

Study Classification

INTERVENTIONAL

Study Start Date

2011-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate whether some features of plaques in coronary arteries predispose the heart muscle to injuries during angioplasty in patients with a narrowing in at least one of the arteries that may need a stent placed during a heart catheterization. Participants undergo a cardiovascular magnetic resonance imaging (MRI) study before the heart catheterization to look for scarring in the heart muscle. During the heart catheterization, participants undergo an intravascular ultrasound (IVUS) exam to look at the make-up of the plaques before the stent placement and the investigators will measure the pressures in the arteries to look at how severe the blockage is. Within 30 days after the heart catheterization, participants will have a second MRI done to look for any new scar in the heart muscle.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronary Disease

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Cardiac MRI Plaque

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

All Patients

All patients undergo the same study procedures

Group Type OTHER

Cardiac MRI

Intervention Type OTHER

Cardiac MRI

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cardiac MRI

Cardiac MRI

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18 to 90 years
* Patients with known obstrucive coronary arterial disease for PCI in a native coronary artery
* Ability and willingness to consent and Authorization for use of personal health information (PHI)
* Ability and willingness to the required follow up procedures

Exclusion Criteria

* An acute myocardial infarction in the vascular territory of interest.
* History of percutaneous coronary intervention in the major epicardial vessel of interest
* Lesion characteristics that preclude IVUS
* The presence of delayed enhancement in the territory of the study vessel on baseline CMR
* Patients with current history of cardiomyopathy which is known to cause enhancement on CMR study
* Patients who are considered hemodynamically unstable based on clinical assessment by the physician
* Patients with Class IV congestive heart failure at time of enrollment
* Patients with poorly controlled hypertension with SBP \>/= 210mmhg and/or DBP \>/=140 hypertension unable to be treated, at time of enrollment
* GFR\</=30 pre-procedure per institutional standards
* Patients with any known co-morbid conditions that is limiting their life expectancy to \< 1year
* A known contraindication to Adenosine, including but not limited to:
* Moderate to severe hyperactive airway disease such as asthma and severe COPD
* Second or third degree AV block
* Known sinus node disease, such as sick sinus syndrome or symptomatic bradycardia
* Known hypersensitivity to Adenosine
* A known contraindication to MRI
* Electronically, magnetically, and mechanically activated implants
* Ferromagnetic or electronically operated active devices like automatic cardioverter defibrillators, and cardiac pacemakers
* Metallic splinters/fragments in sensitive tissues including the eye, brain, spinal cord etc…
* Ferromagnetic haemostatic clips in the central nervous system
* A known contraindication to Gadolinium
* Patients with history of allergic reactions to gadolinium based contrast
* Patients with glomerular filtration rate (GFR) \</= 30ml/min
* Inability or unwillingness to consent and Authorization for use of PHI
* Patients who are unwilling or unable to follow up
* Known pregnancy
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Volcano Corporation

INDUSTRY

Sponsor Role collaborator

GE Healthcare

INDUSTRY

Sponsor Role collaborator

Siemens Medical Solutions

INDUSTRY

Sponsor Role collaborator

Piedmont Healthcare

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Piedmont Heart Institute

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Hawaii

Identifier Type: -

Identifier Source: org_study_id